

## **Informed Consent Statement**

Journal: *World Journal of Clinical Oncology*

Type of Study: *retrospective cohort*

Title: **Cisplatin, Docetaxel, and Cetuximab (TPEx) as First-Line Treatment for Patients with Recurrent or Metastatic Head and Neck Cancer: A Multicenter Real-World Study**

Authors: Agustín Falco, MD<sup>1</sup>; Mariano Leiva, MD<sup>1</sup>; Albano Blanco, MD<sup>1</sup>; Guido Cefarelli, MD<sup>1</sup>; Andrés Rodríguez, MD<sup>1</sup>; Juan Melo, MD<sup>2</sup>; Federico Cayol, MD<sup>2</sup>; Manglio Rizzo, MD, PhD<sup>3</sup>; Alejandro Sola, MD<sup>4</sup>; Hernán Rodríguez Montani, MD<sup>5,6</sup>; Matías Chacón, MD<sup>1</sup>; Diego Enrico, MD<sup>1\*</sup>; and Federico Waisberg, MD<sup>1\*</sup>.

Informed consent statement: Patients were not required to give their informed consent for this study because the analysis used anonymous data on the patient's name, address, date of birth, ward, bed number, hospital number, and other private information.



Diego Enrico, MD

Alexander Fleming Cancer Institute  
Department of Clinical and Translational Research  
Crámer 1180, Buenos Aires, Argentina  
Phone: 54 11 3221-8900  
E-mail: [denrico@alexanderfleming.org](mailto:denrico@alexanderfleming.org)